5 Questions with Kurt Elam, Senior Director, Sales & Marketing for LabOwl

Published on :

Kurt Elam joined ACC/Lab Owl in 2017 with 20+ years of specialty biopharmaceutical experience, focused primarily on oncology, infectious disease, and critical care/ICU medicine. He has overseen and managed the successful launch of over 16 new FDA approved products/compounds or new indications, and worked to gain formulary approval in managed care organizations, thereby improving access for patients.

Spark Therapeutics Expands Visionary Leadership with Appointment of Michael Retterath as Chief Strategy Officer

Published on :

Spark Therapeutics, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY) and a fully integrated, commercial gene therapy company dedicated to challenging the inevitability of genetic disease, today announced the appointment of Michael Retterath as chief strategy officer.